<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Abuse deterrent opioids</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Abuse deterrent opioids</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Abuse deterrent opioids</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Rosenquist, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Fishman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1706748224"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prescription opioid abuse represents a large component of the opioid drug crisis in the United States. The rate of fatal overdoses due to oral formulations of semisynthetic opioids (eg, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a>) has risen steadily since 2000, and in 2017 was greater than that of heroin [<a href="#rid1">1</a>].</p><p>Many individuals who abuse opioids progress from an initially legitimate, legal use of oral opioids, to misuse, tolerance, abuse, and possible addiction. Abusers may swallow many pills at once, but may also chew the tablets or crush them to facilitate smoking, inhalation, or intravenous (IV) injection, all of which increase the risks of overdose and addiction. Abuse deterrent formulations (ADFs) of opioids are designed to prevent these altered routes of administration, while retaining efficacy with oral administration for legitimate pain relief. Prescription of ADF opioids is controversial because of unanswered questions about their ability to reduce overall opioid abuse, and their higher cost. ADFs neither prevent individuals from taking the drugs in higher doses than prescribed (which is the most common form of opioid abuse), change the addictive properties of the drug, nor prevent the other adverse, multisystem effects of opioids.</p><p>This topic will discuss the technologies used, available formulations, and efficacy of ADF opioids for reducing opioid misuse and abuse. Opioid use disorder and abuse of prescription opioids is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Opioid analgesics'</a>.)</p><p class="headingAnchor" id="H3441319018"><span class="h1">GOALS FOR ABUSE DETERRENT FORMULATION</span><span class="headingEndMark"> — </span>The primary goal for an abuse deterrent formulation (ADF) is to deter or dissuade an individual from chewing the drug or using it for inhalation or intravenous (IV) abuse. These latter routes of administration are associated with an increased risk of respiratory depression and fatal overdose compared with oral administration [<a href="#rid2">2</a>], particularly because of the high dose of opioid that is concentrated in extended-release formulations. Chewing, inhalation, and IV routes of drug administration rapidly achieve a high blood level and greater degree of rewarding effects [<a href="#rid3">3,4</a>], and therefore may increase the risk of addiction and abuse. Non-oral routes of administration are also associated with a variety of other health consequences, including damage to nasal and oral structures [<a href="#rid5">5,6</a>] and blood-borne infections (eg, human immunodeficiency virus, hepatitis, and endocarditis) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1112708339"><span class="h1">ABUSE DETERRENT TECHNOLOGIES</span><span class="headingEndMark"> — </span>One or more abuse deterrent technologies are used for the abuse deterrent formulations (ADFs) currently available in the United States and approved for ADF labeling by the US Food and Drug Administration (FDA)  (<a class="graphic graphic_table graphicRef115620" href="/z/d/graphic/115620.html" rel="external">table 1</a>). There are several abuse deterrent preparations available in Canada, none of which have been approved for tamper resistant labelling by Health Canada.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical/chemical barriers </strong>– The most common ADF technology employs either physical or chemical barriers, or both. Physical barriers are used to prevent chewing, crushing, cutting, or grinding of the tablet. Chemical barriers (eg, gelling agents) resist penetration and dissolution by water or other solvents, and may change the form of the active drug to render it difficult to inhale or inject. As an example, with one chemical barrier technology, the active drug turns into a viscous gel when exposed to a liquid, making it difficult for the abuser to use a syringe to inject the drug [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agonist/antagonist combinations </strong>–<strong> </strong>An opioid antagonist can be added to the agonist drug. Opioid antagonists are not effectively absorbed when swallowed, and do not counteract the opioid agonist when taken as intended [<a href="#rid9">9</a>]. However, when the manipulated drug is injected or inhaled, the antagonist is effective at reducing or eliminating the euphoria associated with the agonist. The combination drug that includes <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> (Suboxone), used for pharmacotherapy of opioid use disorder, works by this mechanism. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Transmucosal formulations'</a>.)</p><p></p><p>Additional formulations for abuse deterrence include aversion, whereby substances are added to produce unpleasant effects of the drug when misused; unconventional opioid delivery systems such as sustained-release depot injectable formulations or subcutaneous implants that are difficult to manipulate; prodrugs or new molecular entities that must undergo enzymatic activation or other chemical transformations in the gastrointestinal tract in order to release the active opioid [<a href="#rid10">10,11</a>]; combinations of two or more technologies; or novel approaches or new technologies.</p><p class="headingAnchor" id="H2151009758"><span class="h1">ABUSE DETERRENT FORMULATION APPROVAL PROCESS</span><span class="headingEndMark"> — </span>The FDA strongly recommends three types of premarket studies plus postmarket evaluation for abuse deterrent formulation (ADF) labeling [<a href="#rid12">12</a>]. The premarket studies use healthy, non-addicted, recreational drug users between 18 and 55 years of age, and are designed to evaluate the bio-equivalency of the active drug, integrity of the deterrent properties, the ease with which the altered drug can be drawn into and injected from a syringe for intravenous (IV) use, and the "likeability" of a manipulated ADF.</p><p>Postmarketing studies evaluate the real-world effect of the ADF on reduction of abuse, misuse, adverse clinical outcomes, overdose, and death. Postmarketing studies have been completed for the ADF of extended-release <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> (OxyContin), which was the first available ADF, but the results are inconclusive. (See <a class="local">'Efficacy'</a> below.)</p><p>The FDA approves abuse deterrent labeling for specific routes of drug use (ie, oral, nasal, or IV) based on clinical studies. The routes of drug use approved for abuse deterrent labeling for available ADF opioids are shown in a table  (<a class="graphic graphic_table graphicRef115620" href="/z/d/graphic/115620.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H922157710"><span class="h1">ABUSE DETERRENT OPIOID FORMULATIONS</span><span class="headingEndMark"> — </span>Several opioid preparations with abuse deterrent formulation (ADF) labeling are available in the United States and are shown in a table.  (<a class="graphic graphic_table graphicRef115620" href="/z/d/graphic/115620.html" rel="external">table 1</a>) They include generic equivalents for extended-release <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> and for extended-release <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a>. One of the US Food and Drug Administration (FDA) approved ADFs with oxycodone (Targin) is available in Canada but not the United States.</p><p>An ADF of extended-release <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> (OxyContin) was the first opioid approved for ADF labeling, and is the most widely prescribed ADF opioid. The available ADF opioids, the technology used for abuse deterrence, and available doses are shown in a table  (<a class="graphic graphic_table graphicRef115620" href="/z/d/graphic/115620.html" rel="external">table 1</a>).</p><p>An <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a> preparation with abuse deterrent technology, reformulated Opana ER, was withdrawn from the market by the manufacturer in 2017 [<a href="#rid13">13</a>] because of reports of thrombotic thrombocytopenic purpura [<a href="#rid14">14,15</a>], and an outbreak of human immunodeficiency virus infection [<a href="#rid16">16</a>] associated with intravenous abuse of the manipulated preparation. Reformulated Opana ER never acquired FDA ADF labeling due to concerns about safety and efficacy [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1219939515"><span class="h1">EFFICACY</span><span class="headingEndMark"> — </span>Abuse deterrent formulation (ADF) probably reduces the abuse of a specific opioid but may also drive abusers to select a different non-ADF opioid, an intravenous opioid (eg, heroin), or another type of illegal psychostimulant (eg, cocaine).</p><p class="headingAnchor" id="H2549019028"><span class="h2">Efficacy of technology</span><span class="headingEndMark"> — </span>ADF labeling requires demonstration that the abuse deterrent technology makes it more difficult to extract the active drug, more difficult to draw the extracted drug into a syringe and inject it from a syringe, and that the manipulated drug is less "likeable" than the non-ADF equivalent [<a href="#rid12">12</a>]. (See <a class="local">'Abuse deterrent formulation approval process'</a> above.)</p><p class="headingAnchor" id="H507874033"><span class="h2">Real world efficacy</span><span class="headingEndMark"> — </span>Real world efficacy of ADF technology may be reduced for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>ADF does <strong>not</strong> prevent patients from taking increased quantities of the ADF formulation and therefore higher doses than prescribed, which is the most common form of opioid misuse [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ADF does <strong>not</strong> change the addictive property of the active drug.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ADFs are <strong>not</strong> abuse-proof, and online forums for abusing opioids have posted instructions for subverting some ADF technologies [<a href="#rid19">19-21</a>]. </p><p></p><p class="headingAnchor" id="H1154338585"><span class="h3">Effect of abuse deterrent formulation on abuse of specific drug</span><span class="headingEndMark"> — </span>The postmarketing studies that have been completed for reformulated extended-release (ER) <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> (OxyContin) have been inconclusive and have reported mixed results. It is unclear whether prescription of an ADF opioid rather than a non-ADF opioid reduces the risk of abuse, addiction, or overdose in opioid naïve patients or in those who do not abuse opioids at the time of prescription. There are no postmarket studies of abuse that have been conducted in cohorts of patients who are newly prescribed ADF and non-ADF opioids. There are also no studies of any type that have compared rates of addiction in ADF versus non-ADF users.</p><p>Most of the studies of the effects of reformulated OxyContin have reported a reduction in the rate of OxyContin abuse after reformulation, with reported reductions of 12 to 75 percent [<a href="#rid22">22-26</a>]. These studies are retrospective, and have been based on poison control center calls, reports from individuals in substance abuse programs, population-based drug use surveys, medical claims databases, and data from drug diversion programs; this data has been collected over time periods in which other interventions aimed at opioid abuse may have occurred.</p><p>It appears that very few individuals who abused OxyContin prior to reformulation ceased drug abuse because of the abuse deterrent formulation. In one survey of patients with opioid abuse disorder, 3 percent of patients reported that they stopped drug abuse because of OxyContin reformulation, whereas 66 percent of patients either continued to abuse OxyContin (either orally or by manipulation) or switched to other drugs [<a href="#rid22">22</a>]. (See <a class="local">'Switch to other opioids or heroin'</a> below.)</p><p>An industry-sponsored retrospective database study compared opioid related adverse outcomes in approximately 4850 patients who were prescribed extended abuse deterrent <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> (Embeda, extended-release morphine with sequestered <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> hydrochloride) with outcomes in 10,350 patients who received non-abuse-deterrent extended-release morphine [<a href="#rid27">27</a>]. Prescription of the abuse deterrent formulation was associated with lower incidences of abuse or dependence and non-fatal opioid related overdose.</p><p class="headingAnchor" id="H588504058"><span class="h3">Efficacy for overall opioid abuse</span><span class="headingEndMark"> — </span>The impact of ADF technology on opioid misuse and abuse at the societal level is difficult to determine because these technologies are part of evolving multipronged strategies to combat the opioid epidemic.</p><p class="bulletIndent1">ADFs represent only a small portion of the available and prescribed opioid products in the United States (US), and therefore may have a limited impact on overall rates of opioid abuse [<a href="#rid28">28</a>]. Ninety-six percent of all opioid products prescribed in the United States in 2015 (predominantly immediate-release [IR] formulations) lacked abuse deterrent properties. In 2016, prescriptions for ADF opioids represented about 20 percent of all dispensed extended-release opioids [<a href="#rid12">12</a>], though availability of ADFs in the US may increase as state legislatures or health insurance companies mandate or encourage ADF prescription. (See <a class="local">'State legislation'</a> below.)</p><p></p><p>However, even if all prescription opioids were changed to ADFs, illicit opioids including heroin, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, and other synthetic opioids would still be available and this change could drive users from prescription to illicit drug abuse.</p><p class="headingAnchor" id="H1639375495"><span class="h1">NEGATIVE CONSEQUENCES OF ABUSE DETERRENT OPIOID FORMULATION</span></p><p class="headingAnchor" id="H229668143"><span class="h2">Switch to other opioids or heroin</span><span class="headingEndMark"> — </span>As an alternative to abuse deterrent formulations (ADFs), many abusers have switched to other prescription opioids, or have chosen to inject or inhale heroin, which is increasingly available and less expensive than ADF pills [<a href="#rid29">29</a>], and is a more significant public health issue than abuse of prescription opioids. (See  <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">"Prevention of lethal opioid overdose in the community", section on 'Epidemiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increase in non-ADF opioids </strong>– A number of studies have reported an increase in the use of non-ADF opioids that are easier to abuse after introduction of reformulated OxyContin [<a href="#rid22">22-26,30-32</a>]. As an example, in one study, opioid use and abuse were assessed after introduction of the ADF <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> (reformulated OxyContin) in patients who were taking the ER preparation continuously prior to reformulation [<a href="#rid31">31</a>]. Thirty percent of patients avoided switching to ADF opioid, and instead changed to non-ADF extended-release (ER) opioids or immediate-release/short acting opioids or stopped taking prescription opioids (presumably many of whom switched to illicit opioids). The diagnosed opioid abuse rates were higher in patients who avoided switching to ADFs than in patients who transitioned to ADFs (6.7 percent for those who switched to other ER opioids, 10.9 percent for those who discontinued ER prescription opioids, and 11.3 percent for those who switched to immediate-release opioids, compared with 3.5 percent in patients who transitioned to ADF oxycodone).</p><p></p><p>Evidence that ADFs have been related to an increase in heroin use includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A survey of prescription opioid abusers who were entering treatment programs reported that after the reformulation of OxyContin to ADF, while OxyContin use fell by approximately 35 percent, use of other opioids (including high-potency <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> and <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>) increased by approximately 50 percent, and heroin use nearly doubled [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A survey from Purdue Pharma, maker of OxyContin, reported a 42 percent increase in heroin abuse after OxyContin was redesigned as an ADF [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2017 study estimated that up to 80 percent of the threefold increase in heroin mortality since 2010 could be attributed to the formulation change of OxyContin [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H3016569388"><span class="h2">Cost</span><span class="headingEndMark"> — </span>For some opioids the ADF is significantly more expensive than the non-ADF equivalent, particularly for <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> preparations. Costs to patients for ADFs vary depending on the retail outlet, insurance coverage and copays, and availability of drug manufacturer, or pharmacy discounts. Some states have mandated insurance coverage for ADF opioids. Many insurance plans require preapproval for ADF prescription. (See <a class="local">'State legislation'</a> below.)</p><p>The high cost of some ADFs has prompted analyses of the overall value of these drugs, considering indirect cost savings such as emergency room visits, hospitalizations, overdoses, and abuse treatment programs, in addition to ADF drug costs. Such analysis is necessarily based on assumptions about the efficacy of ADFs for deterring abuse and related clinical outcomes, without reliable supporting data. (See <a class="local">'Real world efficacy'</a> above.)</p><p class="headingAnchor" id="H2339187692"><span class="h1">STATE LEGISLATION</span><span class="headingEndMark"> — </span>State legislatures have enacted or are considering legislation requiring that clinicians prescribe or pharmacists dispense abuse deterrent formulation (ADF) opioids where they are available [<a href="#rid35">35</a>]. In 2014, Massachusetts became the first state to pass legislation that requires pharmacies to substitute ADFs by default for chemically equivalent non-ADF opioid prescriptions unless specifically directed otherwise by the prescriber, and to require insurance carriers to cover these ADFs with no additional cost burden to patients [<a href="#rid36">36</a>]. Clinicians should be aware of the regulations that apply in their states.</p><p>Data on the impact of these state policy interventions are limited and inconsistent [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H1520037009"><span class="h1">INDICATIONS FOR ABUSE DETERRENT FORMULATION PRESCRIPTION</span><span class="headingEndMark"> — </span>We do not routinely prescribe abuse deterrent formulation (ADF) opioids rather than non-ADF opioids. The decision to prescribe ADF opioids should be individualized, but data are not available that would stratify risk and determine which patients should receive these preparations [<a href="#rid38">38</a>]. Use of ADFs should never be a substitute for other relevant risk management approaches or risk mitigation tools. (See  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Monitoring and risk management strategies during trial'</a>.)</p><p>Prescription of abuse deterrent opioid formulations has declined since reformulated oxycontin became available in 2010, and remains a very small fraction of available opioids [<a href="#rid39">39,40</a>].</p><p>The clinician who is truly concerned about abuse by the intended recipient should reconsider prescribing an opioid at all. An ADF may be indicated if there is high risk of diversion, such as a debilitated patient in a living situation that allows others access to the patient’s medications.</p><p>Whereas ADFs make abuse more difficult for patients who are prescribed opioids for chronic pain, individuals already abusing opioids may switch to other illicit opioids (including heroin or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) if a specific opioid is replaced with an ADF. The added cost to the health care system (and possibly the patient) is substantial. The same heightened vigilance is required whether an ADF or regular opioid is prescribed. (See <a class="local">'Real world efficacy'</a> above.)</p><p>Further real world studies are required to elucidate the role of abuse deterrent opioids in attempts to curb the opioid epidemic.</p><p class="headingAnchor" id="H1317376965"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for abuse deterrent technology </strong>–<strong> </strong>Abuse deterrent formulations (ADFs) of opioids are designed to prevent unintended routes of administration, while retaining efficacy with oral administration for legitimate pain relief. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technologies </strong>–<strong> </strong>ADF technologies are intended to either make manipulation of oral medications (eg, chewing, inhalation, or injection) more difficult, or to make the drug less rewarding once manipulated. Available ADF opioids employ the following technologies (see <a class="local">'Abuse deterrent technologies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical barriers that prevent chewing, crushing, cutting, or grinding of the tablet</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemical barriers that prevent dissolution with solvent and therefore make injection or inhalation more difficult</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Incorporation of an opioid antagonist that is inactive when taken orally but antagonizes the agonist opioid when the drug is manipulated</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Availability </strong>–<strong> </strong>Several opioids with ADF labeling are available in the US and are shown in a table  (<a class="graphic graphic_table graphicRef115620" href="/z/d/graphic/115620.html" rel="external">table 1</a>). (See <a class="local">'Abuse deterrent opioid formulations'</a> above.)</p><p></p><p class="bulletIndent1">ADFs in the US are branded drugs that are significantly more expensive than non-ADF counterparts, and may or may not be paid for by health insurance. (See <a class="local">'Cost'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>–<strong> </strong>ADF probably reduces the abuse of a specific opioid, but may also drive abusers to select a different non-ADF opioid or heroin. Real world efficacy of ADFs may be reduced for the following reasons (see <a class="local">'Real world efficacy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ADFs do <strong>not</strong> prevent individuals from taking multiple pills</p><p class="bulletIndent2"><span class="glyph">•</span>ADF does <strong>not</strong> change the addictive properties of the active drug</p><p class="bulletIndent2"><span class="glyph">•</span>ADF technology can be subverted</p><p class="bulletIndent2"><span class="glyph">•</span>As an alternative to ADFs, many abusers have switched to using other opioids or heroin</p><p class="bulletIndent2"><span class="glyph">•</span>ADFs represent a small portion of prescribed opioids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Legislation regarding ADF opioids </strong>–<strong> </strong>Some state legislatures have enacted or are considering regulations that govern the prescription of ADF opioids. (See <a class="local">'State legislation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>–<strong> </strong>We do not routinely prescribe ADF opioids rather than non-ADF opioids, unless required by law. Use of ADFs should never be a substitute for other relevant risk management approaches or risk mitigation tools. (See <a class="local">'Indications for abuse deterrent formulation prescription'</a> above.)</p><p></p><p class="headingAnchor" id="H1930078693"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ronald S Litman, DO, ML (deceased), who contributed as an author to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Scholl L, Seth P, Kariisa M, et al. Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2018; 67:1419.</a></li><li><a class="nounderline abstract_t">Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend 2017; 175:140.</a></li><li><a class="nounderline abstract_t">Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011; 37:205.</a></li><li class="breakAll">McAnally HB. Attenuating the Agent: Reducing Opioid “Virulence”. In: Opioid Dependence, Springer, 2018.</li><li><a class="nounderline abstract_t">Yewell J, Haydon R, Archer S, Manaligod JM. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol 2002; 111:174.</a></li><li><a class="nounderline abstract_t">Alexander D, Alexander K, Valentino J. Intranasal hydrocodone-acetaminophen abuse induced necrosis of the nasal cavity and pharynx. Laryngoscope 2012; 122:2378.</a></li><li><a class="nounderline abstract_t">Powell D, Alpert A, Pacula RL. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. Health Aff (Millwood) 2019; 38:287.</a></li><li class="breakAll">Purdue Pharma LP. Hysingla ER (hydrocodone bitartrate) Extended-Release tablets https://hysinglaer.com/opioid-abuse-deterrence-studies.html.</li><li><a class="nounderline abstract_t">Davis M, Goforth HW, Gamier P. Oxycodone combined with opioid receptor antagonists: efficacy and safety. Expert Opin Drug Saf 2013; 12:389.</a></li><li><a class="nounderline abstract_t">Kirkpatrick DL, Schmidt WK, Morales R, et al. In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. J Opioid Manag 2017; 13:39.</a></li><li><a class="nounderline abstract_t">Maincent J, Zhang F. Recent advances in abuse-deterrent technologies for the delivery of opioids. Int J Pharm 2016; 510:57.</a></li><li class="breakAll">US Food and Drug Administration. Abuse-deterrent opioids—evaluation and labeling. Guidance for industry. 2015. https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf (Accessed on June 19, 2017).</li><li class="breakAll">US Food and Drug Administration. FDA requests removal of Opana ER for risks related to abuse, 2017. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm562401.htm (Accessed on June 19, 2017).</li><li><a class="nounderline abstract_t">Hunt R, Yalamanoglu A, Tumlin J, et al. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood 2017; 129:896.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:1.</a></li><li><a class="nounderline abstract_t">Peters PJ, Pontones P, Hoover KW, et al. HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015. N Engl J Med 2016; 375:229.</a></li><li class="breakAll">US Food and Drug Administration: Postmarketing safety issues related to reformulated Opana ER®. 2017. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM545760.pdf (Accessed on June 20, 2017).</li><li><a class="nounderline abstract_t">Butler SF. Reply to commentary. J Pain 2013; 14:361.</a></li><li><a class="nounderline abstract_t">Vosburg SK, Haynes C, Besharat A, Green JL. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program. Pharmacoepidemiol Drug Saf 2017; 26:1044.</a></li><li><a class="nounderline abstract_t">McNaughton EC, Coplan PM, Black RA, et al. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. J Med Internet Res 2014; 16:e119.</a></li><li><a class="nounderline abstract_t">McNaughton EC, Black RA, Zulueta MG, et al. Measuring online endorsement of prescription opioids abuse: an integrative methodology. Pharmacoepidemiol Drug Saf 2012; 21:1081.</a></li><li><a class="nounderline abstract_t">Cicero TJ, Ellis MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. JAMA Psychiatry 2015; 72:424.</a></li><li><a class="nounderline abstract_t">Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013; 14:351.</a></li><li><a class="nounderline abstract_t">Sessler NE, Downing JM, Kale H, et al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf 2014; 23:1238.</a></li><li><a class="nounderline abstract_t">Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain 2013; 14:1122.</a></li><li><a class="nounderline abstract_t">Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367:187.</a></li><li><a class="nounderline abstract_t">Cicero TJ, Mendoza M, Cattaneo M, et al. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. Postgrad Med 2019; 131:225.</a></li><li class="breakAll">Tufts Center for the Study of Drug Development. ADF opioid development, uptake tied to efficacy, regulatory/payer policies, 2017. http://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5aa2b259f9619afb7edc688d/1520611929389/Summary_JulyAugustIR17.pdf.</li><li><a class="nounderline abstract_t">Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav 2017; 74:63.</a></li><li><a class="nounderline abstract_t">Cassidy TA, DasMahapatra P, Black RA, et al. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med 2014; 15:440.</a></li><li><a class="nounderline abstract_t">Michna E, Kirson NY, Shei A, et al. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Curr Med Res Opin 2014; 30:1589.</a></li><li><a class="nounderline abstract_t">Jauncey M, Livingston M, Salmon AM, Dietze P. The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons. Int J Drug Policy 2018; 53:17.</a></li><li><a class="nounderline abstract_t">Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf 2013; 22:1274.</a></li><li class="breakAll">Alpert A, Powell D, Pacula RL. Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids, NBER Working Paper 23031, RAND Corporation, 2017. http://www.nber.org/papers/w23031 (Accessed on July 15, 2017).</li><li class="breakAll">Multistate Insider: States Have Stalled on Potential Opioid Abuse Solution: Deterrent Formulation Drugs. 2017. https://www.multistate.us/blog/state-efforts-have-stalled-on-potential-opioid-abuse-solution-deterrent-formulation-drugs (Accessed on July 21, 2017).</li><li class="breakAll">https://malegislature.gov/Laws/SessionLaws/Acts/2016/Chapter52.</li><li><a class="nounderline abstract_t">Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend 2014; 145:34.</a></li><li class="breakAll">https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm#T1_down.</li><li class="breakAll">Report on abuse-deterrent opioid formulations and access barriers under Medicare. US Food and Drug Administration. https://www.fda.gov/media/140805/download#:~:text=ER%20opioid%20analgesics%20however%2C%20represent,the%20overall%20opioid%20analgesic%20market. (Accessed on November 06, 2023).</li><li><a class="nounderline abstract_t">Brown JR, Oh G, Wang Y, et al. Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018. J Rural Health 2021; 37:23.</a></li></ol></div><div id="topicVersionRevision">Topic 113892 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30605448" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28414990" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517709" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517709" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860072" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Complications of intranasal prescription narcotic abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22965281" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intranasal hydrocodone-acetaminophen abuse induced necrosis of the nasal cavity and pharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715966" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715966" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23534906" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oxycodone combined with opioid receptor antagonists: efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28345745" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™prodrug of oxycodone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27291971" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recent advances in abuse-deterrent technologies for the delivery of opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27291971" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recent advances in abuse-deterrent technologies for the delivery of opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27291971" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recent advances in abuse-deterrent technologies for the delivery of opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864296" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23302815" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468059" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468059" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23548491" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reply to commentary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28653782" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24800858" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777908" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Measuring online endorsement of prescription opioids abuse: an integrative methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760692" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127293" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916486" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816949" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784140" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of abuse-deterrent formulation of OxyContin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30794760" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30794760" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28582659" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Increased use of heroin as an initiating opioid of abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330279" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24738694" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of prescription opioids with abuse-deterrent technology to address opioid abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29268238" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123484" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123484" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123484" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123484" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25454406" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25454406" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25454406" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32686223" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
